ALKERMES reported $36.59M in EBIT for its fiscal quarter ending in September of 2026.





Ebit Change Date
AbbVie USD 6.88B 156M Sep/2026
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
ALKERMES USD 36.59M 102.52M Sep/2026
Amgen USD 4.68B 65M Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Eli Lilly USD 13.09B 635M Sep/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Ionis Pharmaceuticals USD -130M 27.71M Sep/2026
J&J USD 6.47B 1B Sep/2026
Malin Corporation EUR -1.1M 300K Dec/2024
Merck USD 7.33B 6.49B Sep/2026
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Otsuka Holdings JPY 145.39B 4.98B Sep/2026
Ovoca Bio EUR -173K 990K Dec/2025
Pfizer USD 4.85B 5.03B Sep/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026